Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection

AIDS Research and Human Retroviruses

Volumn 24, Issue 5, 2008, Pages 685-694

  Anderson, Jeffrey A ^a   Jiang, Hongyu ^b   Ding, Xiao ^b   Petch, Leslie ^a   Journigan, Terri ^a   Fiscus, Susan A ^a   Haubrich, Richard ^c   Katzenstein, David ^d   Swanstrom, Ronald ^a   Gulick, Roy M ^e  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; DELAVIRDINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CODON; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG EFFICACY; GENE FREQUENCY; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CODON; DISEASE PROGRESSION; DRUG RESISTANCE, VIRAL; GENES, POL; GENETIC MARKERS; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION; PREDICTIVE VALUE OF TESTS; RNA, VIRAL; TREATMENT OUTCOME; UNITED STATES; VIRAL LOAD;

EID: 44349161109     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0127     Document Type: Article

References (53)

1. Gulick RM, Mellors JW, Halvir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-739.
2. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-733.
3. Cameron DW, Heath-Chiozzi M, Danner S, et al.: Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998;351:543-549.
4. Mouton Y, Alfandari S, Valete M, et al.: Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centers. AIDS 1997;11:F101-105.
5. Palella FJ, Delaney KM, Morman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infections. N Engl J Med 1998;338:853-860.
6. Ledergerber B, Egger M, Opravil M, et al.: Clinical progression and virologic failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study. Lancet 1999;353:863-868.
7. Lucas GM, Chaisson RE, and Moore RD: Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:81-87.
8. Bartlett JA, Faith MJ, Demasi R, et al.: An updated systematic overview of triple combination therapy in antiretroviral-naïve HIV-infected adults. AIDS 2006;20:2051-2064.
9. Hammer SM, Saag MS, Schechter M, et al.: Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006;296:827-843.
10. Panel on Clinical Practices for the Treatment of HIV Infection: Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Available at www.aids info.org. October 10, 2006 update.
11. Durant J, Clevenbergh P, Halfon P, et al.: Drug resistance genotyping in HIV-1 therapy: The VIRADAPT randomized controlled trial. Lancet 1999;353:2195-2199.
12. Baxter JD, Mayers DL, Wentworth DN, et al.: A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy: CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000;14:F89-93.
13. Lorenzi P, Opravil M, Hirschel B, et al.: Impact of drug resistance mutations on virologic response to salvage therapy. AIDS 1999;13:F17-21.
14. Middleton T, Smith D, Larder B, et al.: Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy. HIV Clin Trials 2001;2:445-452.
15. Ena J, Ruiz de Apodaca RF, Amador C, Benito C, and Pasquau F: Net benefits of resistance testing directed therapy compared with standard of care in HIV-infected patients with virologic failure: A meta-analysis. Enferm Infecc Microbiol Clin 2006;24:232-237.
16. Gulick RM, Hu XJ, Fiscus SA, et al.: Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. J Infect Dis 2000;182:1375-1384.
17. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, and Shafer RW: Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2003;31:298-303.
18. Swanstrom R, Bosch RJ, Katzenstein D, et al.: Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease-inhibitor-experienced, HIV-1-infected subjects. J Infect Dis 2004;190:886-893.
19. Hughes MD: Analysis and design issues for studies using censored biomarker measurements with an example of viral load measurements in HIV clinical trials. Stat Med 2000;19:3171-3191.
20. Johnson VA, Brun-Vezinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 2006;14:125-130.
21. de Jong JJ, Goudsmit J, Lukashov VV, et al.: Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine 215 of HIV-1 resistant to multiple nucleoside analogs. AIDS 1999;13:75-80.
22. Condra JH, Holder DJ, Schleif WA, et al.: Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol 1996;70:8270-8276.
23. Havlir DV, Hellman NS, Petropoulos CJ, et al.: Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 2000;283:229-234.
24. Bacheler L, van Marck H, Vermeiren H, et al.: The virtual phenotype: A quantitative prediction of HIV drug susceptibility from viral genotype. HIV Med 2003;4:178.
25. Beerenwinkel N, Daumer M, Oette M, et al.: Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res 2003;31:3850-3855.
26. Vercauteren J and Vandamme AM: Algorithms for the interpretation of HIV-1 genotypic drug resistance information. Antiviral Res 2006;71:335-342.
27. Cingolani A, Antinori A, Rizzo MG, et al.: Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: A randomized study (ARGENTA). AIDS 2002;16:369-739.
28. Tural C, Ruiz L, Holtzer C, et al.: Clinical utility of HIV-1 genotyping and expert advice: The Havana trial. AIDS 2002;16:209-218.
29. Novak RM, Chen L, MacArthur RD, et al.: Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naïve patients: Implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis 2005;40:468-474.
30. De Luca AA and Carlo-Federico P: Impact of different HIV resistance interpretation by distinct systems on clinical utility of resistance testing. Curr Opin Infect Dis 2003;16:573-580.
31. De Luca AA, Cingolani A, Di Giambendetto S, et al.: Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis 2003;187:1934-1943.
32. Gallego O, Martin-Carbonero L, Aguero J, de Mendoza C, Corral A, and Soriano V: Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals. J Virol Methods 2004;121:115-118.
33. Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT, and Miller MD: Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 2002;16:1227-1235.
34. Sloot P, Boukhanovsky AV, Keulen W, Tirado-Ramos A, and Boucher CA: A grid-based HIV expert system. J Clin Monit Comput 2005;19:263-278.
35. Torti C, Uccelli MC, Quiros-Roldan E, et al.: Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors. J Clin Virol 2006;35:414-419.
36. Valer L, de Mendoza C, and Soriano V: Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients. J Med Virol 2005;77:460-464.
37. Wang D and Larder B: Enhanced prediction of lopinavir resistance from genotype by use of artificial neural networks. J Infect Dis 2003;188:653-660.
38. Hales G, Birch C, Crowe S, et al.: A randomized trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: The CREST study. PLoS Clin Trials 2006;1:e18.
39. Mazzotta F, Caputo S, Torti C, et al.: Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial. J Acquir Immune Defic Syndr 2003;32:268-280.
40. Perez-Elias MJ, Garcia-Arota I, Munoz V, et al.: Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: A prospective, randomized study. Antiviral Ther 2003;8:577-584.
41. Saracino A, Monno L, Locaputo S, et al.: Selection of antiretroviral therapy guided by genotypic or phenotypic resistance testing: An open-label, randomized, multicenter study (PhenGen). J Acquir Immune Defic Syndr 2004;37:1587-1598.
42. Meynard JL, Vray M, Morand-Joubert L, et al.: Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: A randomized trial. AIDS 2002;16:727-736.
43. Yahi N, Tamalet C, Tourres C, Tivoli N, and Fantini J: Mutation of L210 of HIV-1 reverse transcriptase in patients receiving combination therapy. Incidence, association with other mutations, and effects on the structure of mutated reverse transcriptase. J Biomed Sci 2000;7:507-513.
44. Hanna G, Johnson VA, Kuritzkes DR, et al.: Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J Infect Dis 2000;181:904-911.
45. Marcelin AG, Delaugerre C, Wirden M, et al.: Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J Med Virol 2004;72:162-165.
46. Yahi N, Fantini J, Henry M, Tourres C, and Tamalet C: Structural analysis of reverse transcriptase mutations at codon 215 explains the predominance of T215Y over T215F in HIV-1 variants selected under antiretroviral therapy. J Biomed Sci 2005;12:701-710.
47. Joly V, Descamps D, Peytavin G, et al.: Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs. Antimicrob Agents Chemother 2004;48:172-175.
48. Shulman N, Zolopa AR, Passaro D, et al.: Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: Impact on virological response to efavirenz-based therapy. AIDS 2001;15:1125-1132.
49. Whitcomb JM, Huang W, Limoli K, et al.: Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: Clinical, phenotypic, and genotypic correlates. AIDS 2002;16:F41-47.
50. Shulman NS, Bosch RJ, Mellors JW, Albrecht MA, and Katzenstein DA: Genetic correlates of efavirenz hypersusceptibility. AIDS 2004;18:1781-1785.
51. Clark SA, Shulman NS, Bosch RJ, and Mellors JW: Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors. AIDS 2006;20:981-984.
52. Molla A, Korneyeva M, Gao Q, et al.: Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996;2:760-766.
53. Jimenez L, Resino S, Martinez-Colom A, Bellon JM, Munoz-Fernandez MA, and the Spanish group of Pediatric HIV infection: Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy. J Antimicrob Chemother 2005;56:1081-1086.